Revenue volatility remains extreme, with quarterly figures swinging from $10.8 million in 2026Q1 to near-zero levels in mid-2025, reflecting a lack of structural operating leverage.
| Sales/Revenue | 45.07M | 34.26M | 68.7M | 48.73M | 25.1M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.01M |
| Revenue Growth % | -11.87% | -50.12% | 40.98% | 94.15% | -78.28% | 375.72% | 9.21% | 104.34% | 67.84% | -7.57% | - |
| Cost of Goods Sold | 1.37M | 2.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 8.03% | - | - | - | - | - | - | - | - | - |
| Gross Profit | 43.7M | 31.51M | 68.7M | 48.73M | 25.1M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.01M |
| Gross Margin % | 96.95% | 91.97% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | -54.13% | 40.98% | 94.15% | -78.28% | 375.72% | 9.21% | 104.34% | 67.84% | -7.57% | - |
| Operating Expenses | 82.81M | 83.66M | 94.86M | 92.46M | 87.41M | 154.91M | 134.11M | 109.44M | 58.8M | 28.34M | 15.2M |
| OpEx % of Revenue | - | 244.16% | 138.08% | 189.76% | 348.26% | 134.08% | 552.25% | 492.14% | 540.25% | 437.08% | 216.72% |
| Selling, General & Admin | 30.49M | 32.24M | 35.3M | 39.09M | 41.28M | 39.67M | 36.05M | 27.03M | 13.67M | 8.02M | 6.1M |
| SG&A % of Revenue | - | 94.09% | 51.38% | 80.22% | 164.49% | 34.34% | 148.45% | 121.53% | 125.64% | 123.63% | 86.97% |
| Research & Development | 53.36M | 54.17M | 59.56M | 53.38M | 46.12M | 115.24M | 98.06M | 82.42M | 45.12M | 20.32M | 9.1M |
| R&D % of Revenue | - | 158.1% | 86.7% | 109.54% | 183.77% | 99.75% | 403.79% | 370.61% | 414.61% | 313.45% | 129.75% |
| Other Operating Expenses | -1.04M | -2.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -39.11M | -52.15M | -26.16M | -43.74M | -62.31M | -39.38M | -109.83M | -87.2M | -47.91M | -21.97M | -8.83M |
| Operating Margin % | -86.77% | -152.19% | -38.08% | -89.76% | -248.26% | -34.08% | -452.25% | -392.14% | -440.25% | -338.9% | -125.84% |
| Operating Income Growth % | - | -99.33% | 40.18% | 29.81% | -58.24% | 64.15% | -25.94% | -82.01% | -118.04% | -148.91% | - |
| EBITDA | -36.42M | -49.4M | -21.59M | -35.48M | -53.3M | -29.18M | -100.02M | -81.89M | -45.56M | -20.54M | -8.19M |
| EBITDA Margin % | -80.81% | -144.16% | -31.42% | -72.82% | -212.38% | -25.26% | -411.84% | -368.23% | -418.62% | -316.76% | -116.72% |
| EBITDA Growth % | 9.47% | -128.84% | 39.16% | 33.44% | -82.68% | 70.83% | -22.14% | -79.74% | -121.81% | -150.84% | - |
| D&A (Non-Cash Add-back) | 2.69M | 2.75M | 4.58M | 8.26M | 9M | 10.2M | 9.81M | 5.32M | 2.35M | 1.44M | 640K |
| EBIT | -34.05M | -52.15M | 8.95M | -40.3M | -71.8M | -30.47M | -109.01M | -92.69M | -46.04M | -21.86M | -8.26M |
| Net Interest Income | 2.54M | 2.82M | 4.98M | 5.46M | 2.36M | 76K | 822K | 4.08M | 1.88M | 872K | 0 |
| Interest Income | 3.92M | 4.24M | 6.76M | 7.69M | 3.47M | 208K | 822K | 4.27M | 1.88M | 872K | 570K |
| Interest Expense | 1.38M | 1.42M | 1.78M | 2.23M | 1.11M | 132K | 0 | 182K | 0 | 0 | 0 |
| Other Income/Expense | -5.37M | 5.54M | 33.33M | 1.21M | -10.6M | 8.77M | 822K | -5.67M | 1.88M | 872K | 572K |
| Pretax Income | -44.48M | -46.61M | 7.17M | -42.53M | -72.91M | -30.6M | -109.01M | -92.88M | -46.04M | -21.1M | -8.26M |
| Pretax Margin % | -98.7% | -136.03% | 10.43% | -87.28% | -290.5% | -26.49% | -448.86% | -417.65% | -423.02% | -325.45% | -117.69% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.06% |
| Net Income | -44.48M | -46.61M | 7.17M | -61.32M | -111.64M | -30.6M | -109.01M | -92.88M | -46.04M | -21.1M | -8.25M |
| Net Margin % | -98.7% | -136.03% | 10.43% | -125.84% | -444.8% | -26.49% | -448.86% | -417.65% | -423.02% | -325.45% | -117.62% |
| Net Income Growth % | -102.33% | -750.33% | 111.69% | 45.07% | -264.8% | 71.93% | -17.37% | -101.74% | -118.16% | -155.75% | - |
| Net Income (Continuing) | -44.48M | -46.61M | 7.17M | -42.53M | -72.91M | -30.6M | -109.01M | -92.88M | -46.04M | -21.1M | -8.25M |
| Discontinued Operations | 0 | 0 | 0 | -18.79M | -38.73M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.81 | -3.63 | 1.04 | -15.96 | -38.10 | -15.60 | -62.85 | -59.50 | -28.17 | -18.81 | -0.49 |
| EPS Growth % | -56.96% | -449.04% | 106.52% | 58.11% | -144.23% | 75.18% | -5.63% | -111.22% | -49.76% | -3738.78% | - |
| EPS (Basic) | - | -3.63 | 1.05 | -15.96 | -38.10 | -15.60 | -62.85 | -59.50 | -28.17 | -18.81 | -0.49 |
| Diluted Shares Outstanding | 24.63M | 12.83M | 6.88M | 3.84M | 2.93M | 1.96M | 1.73M | 1.4M | 1.63M | 1.12M | 16.74M |
| Basic Shares Outstanding | 24.63M | 12.83M | 6.83M | 3.84M | 2.93M | 1.96M | 1.73M | 1.4M | 1.63M | 1.12M | 16.74M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Lumpy milestone-dependent revenue
As reported in recent financial filings, Precision BioSciences exhibits extreme revenue lumpiness, with quarterly figures swinging from $10.8 million in 2026Q1 to near-zero levels in mid-2025, reflecting the inherent unpredictability of milestone-based collaboration payments rather than a consistent, organic growth trajectory for the ARCUS platform.
The company's revenue profile is entirely dependent on the timing of clinical and regulatory milestones from pharmaceutical partners. This creates a non-linear growth pattern that makes period-over-period comparisons largely irrelevant for assessing underlying operational health or commercial momentum.
Based on the company's income statement data, R&D expenses have remained consistently high, averaging over $13 million per quarter, which highlights the significant capital commitment required to advance the ARCUS platform despite the absence of reliable, recurring revenue streams to offset these fixed operational costs.
Management maintains a rigid cost structure focused on laboratory operations and clinical trial execution. This expense discipline is necessary for platform development but leaves the firm highly vulnerable to cash depletion during periods where milestone payments fail to materialize.
According to historical income statements, Precision BioSciences lacks meaningful operating leverage, as operating margins frequently plummet into triple-digit negative territory during quarters without significant licensing inflows, demonstrating that the current business model is not yet capable of scaling profitably through its existing research-heavy cost base.
The lack of a scalable revenue engine means that operating expenses continue to outpace gross profit generation in most periods. Investors should monitor whether the pivot to in vivo programs can eventually lead to more efficient cost absorption or if the current burn rate will persist indefinitely.
As indicated by the provided financial data, net income is heavily influenced by the timing of lumpy collaboration revenue and non-cash stock-based compensation, which obscures the true underlying cash burn and makes reported EPS a poor indicator of the company's actual operational performance or long-term viability.
The wide variance in quarterly net income, ranging from significant losses to occasional profits, is primarily an accounting artifact of revenue recognition rules. Analysts should focus on cash usage metrics rather than GAAP earnings to gauge the true runway of the business.
Based on the reported figures, the primary risk to the income statement is the potential for prolonged gaps between milestone payments, which may force the company to rely on dilutive equity financing to sustain its high-cost R&D operations in the absence of a commercial product.
Short-term observers may point to the high gross margins as a sign of strength, but this ignores the reality that the company has yet to prove it can generate sustainable, non-lumpy cash flow. The reliance on external partners for survival remains the most significant threat to long-term shareholder value.
Quick answers to the most common questions about buying DTIL stock.
For fiscal year 2025, Precision BioSciences, Inc. (DTIL) reported total revenue of $34.3M. This represents a 388.4% increase compared to $7.0M in 2016.
Precision BioSciences, Inc. (DTIL) reported a net loss of $46.6M for the fiscal year ending 2025.
Precision BioSciences, Inc. (DTIL) reported an operating income of $-52.1M, resulting in an operating profit margin of -152.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Precision BioSciences, Inc. (DTIL) generated $31.5M in gross profit for the year, representing a gross profit margin of 92.0%. This demonstrates the company's core pricing power and production efficiency.